TELA Bio (NASDAQ:TELA – Get Free Report) and Trinity Biotech (NASDAQ:TRIB – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.
Analyst Recommendations
This is a summary of current recommendations for TELA Bio and Trinity Biotech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TELA Bio | 1 | 1 | 4 | 0 | 2.50 |
| Trinity Biotech | 1 | 0 | 0 | 0 | 1.00 |
TELA Bio presently has a consensus price target of $2.14, indicating a potential upside of 122.29%. Given TELA Bio’s stronger consensus rating and higher possible upside, analysts clearly believe TELA Bio is more favorable than Trinity Biotech.
Valuation and Earnings
This table compares TELA Bio and Trinity Biotech”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TELA Bio | $78.18 million | 0.56 | -$38.83 million | ($0.74) | -1.30 |
| Trinity Biotech | $43.78 million | 0.11 | -$37.38 million | ($44.26) | -0.13 |
Trinity Biotech has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
TELA Bio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Institutional and Insider Ownership
94.3% of TELA Bio shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 1.1% of TELA Bio shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares TELA Bio and Trinity Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TELA Bio | -53.57% | -1,320.81% | -55.71% |
| Trinity Biotech | -70.06% | N/A | -32.13% |
Summary
TELA Bio beats Trinity Biotech on 9 of the 14 factors compared between the two stocks.
About TELA Bio
TELA Bio, Inc. is a medical technology company that develops and commercializes advanced tissue-reinforcement products for soft-tissue repair and reconstruction. The company’s products are designed to support the repair of damaged or weakened tissue while preserving a more natural tissue response. TELA Bio’s principal product platform is OviTex Reinforced Tissue Matrix, which combines biologic tissue with polymer reinforcement in a proprietary, textile-like design. OviTex products are used in procedures involving hernia and abdominal wall repair, as well as other soft-tissue reconstruction applications.
About Trinity Biotech
Trinity Biotech plc is a medical diagnostics company headquartered in Dublin, Ireland, and listed on the Nasdaq under the symbol TRIB. The company develops, manufactures and markets diagnostic products used by clinical laboratories, hospitals, physicians and other healthcare providers. Its product portfolio has historically focused on infectious disease testing, including assays for HIV and other conditions, as well as clinical chemistry, autoimmune disease and diabetes-related diagnostics. Trinity Biotech has also offered point-of-care testing systems and products used in areas such as hemoglobin A1c testing and CD4 cell counting.
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.
